Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRX-2, Cyclophosphamide, and Nivolumab in Advanced Hepatocellular Carcinoma
NCT03655002Phase 1Active, not recruiting
- Sponsor
- City of Hope
- Start
- May 2019
- Primary completion
- Mar 2027
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of citoplurikin in hepatocellular carcinoma (HCC), sponsored by City of Hope. Primary endpoints: Recommended phase II dose at 28 days and Incidence of adverse events at 2 years. Started May 2019; status: active, not recruiting.
02
Drugs
citoplurikin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03655002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03655002.